Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07854639) titled 'A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma' on Sept. 27.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Peking University First Hospital

Condition: Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sezary Syndrome

Intervention: Drug: Zeprumetostat Tablets

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 31, 2026

Target Sample Size: 33

Countries of Recruitment: China

To know more, ...